按患者体型调整CT剂量:实施2017年更新的ACR体型特异性诊断参考水平
该回顾性研究利用自动CT剂量监测系统,分析2016年7月至2017年4月本院胸部及腹盆部CT剂量数据,对照2017年更新的基于水当量直径(Dw)和体型特异性剂量估计(SSDE)的ACR诊断参考水平(DRL)。共纳入3860例检查,多数方案的平均SSDE和CTDIvol低于更新DRL,但Dw 37-41 cm患者行平扫腹盆部CT时SSDE和CTDIvol超过DRL。
要点
- 多数胸部及腹盆部CT方案的平均SSDE和CTDIvol低于2017年更新的ACR DRL。
- 仅Dw 37-41 cm患者行平扫腹盆部CT时SSDE和CTDIvol超过ACR DRL。
- 按Dw体型分组分析可识别剂量可优化的患者亚组。
核心结论
- 本院胸部及腹盆部CT方案的平均SSDE和CTDIvol低于2017年更新的ACR DRL;体型特异性亚组分析显示各CT方案和患者体型组间SSDE和CTDIvol差异较大,大体型患者(Dw 37-41 cm)平扫腹盆部CT超过DRL。
研究设计与样本
- 回顾性研究,纳入2016年7月至2017年4月期间所有胸部CT(含或不含对比剂)、肺动脉CT及腹盆部CT(含或不含对比剂),共3860例检查(平均年龄62.1±16.4岁,Dw 29.0±3.3 cm)。使用先前验证的本院开发Matlab软件自动计算Dw和SSDE并存入CT剂量监测系统,以SSDE和CTDIvol为剂量参数对照2017年更新的ACR DRL(体型组:21-25 cm、25-29 cm、29-33 cm、33-37 cm、37-41 cm)。
诊断标准与关键数值
- 以2017年更新的ACR DRL为参考,各方案平均SSDE和CTDIvol占DRL的百分比分别为:平扫胸部CT SSDE 43.3±26.4%、CTDIvol 45.1±27.9%;增强胸部CT SSDE 52.3±23.1%、CTDIvol 52.0±23.1%;肺动脉CT SSDE 68.8±29.5%、CTDIvol 70.0±31.0%;平扫腹盆部CT SSDE 41.9±29.2%、CTDIvol 43.3±31.3%;增强腹盆部CT SSDE 56.8±22.2%、CTDIvol 58.8±24.4%。
临床应用与阅片要点
- 平扫腹盆部CT中Dw 21-25 cm组剂量相对DRL最低(SSDE 30.4±21.8%,CTDIvol 30.8±21.4%);平扫腹盆部CT中Dw 37-41 cm组超过ACR DRL(SSDE 100.3±59.0%,CTDIvol 107.1±63.5%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To use an automatic computed tomography (CT) dose monitoring system to analyze the institutional chest and abdominopelvic CT dose data as regards the updated 2017 American College of Radiology (ACR) diagnostic reference levels (DRLs) based on water-equivalent diameter (Dw) and size-specific dose estimates (SSDE) to detect patient-size subgroups in which CT dose can be optimized.
MATERIALS AND METHODS: All chest CT examinations performed between July 2016 and April 2017 with and without contrast material, CT of the pulmonary arteries, and abdominopelvic CT with and without contrast material were included in this retrospective study. Dw and SSDE were automatically calculated for all scans using a previously validated in-house developed Matlab software and stored into our CT dose monitoring system. CT dose data were analyzed as regards the updated ACR DRLs (size groups: 21-25 cm, 25-29 cm, 29-33 cm, 33-37 cm, 37-41 cm). SSDE and volumetric computed tomography dose index (CTDIvol) were used as CT dose parameter.
RESULTS: Overall, 30,002 CT examinations were performed in the study period, 3860 of which were included in the analysis (mean age 62.1 ± 16.4 years, Dw 29.0 ± 3.3 cm; n = 577 chest CT without contrast material, n = 628 chest CT with contrast material, n = 346 CT of chest pulmonary, n = 563 abdominopelvic CT without contrast material, n = 1746 abdominopelvic CT with contrast material). Mean SSDE and CTDIvol relative to the updated DRLs were 43.3 ± 26.4 and 45.1 ± 27.9% for noncontrast chest CT, 52.3 ± 23.1 and 52.0 ± 23.1% for contrast-enhanced chest CT, 68.8 ± 29.5 and 70.0 ± 31.0% for CT of pulmonary arteries, 41.9 ± 29.2 and 43.3 ± 31.3% for noncontrast abdominopelvic CT, and 56.8 ± 22.2 and 58.8 ± 24.4% for contrast-enhanced abdominopelvic CT. Lowest dose compared to the DRLs was found for the Dw group of 21-25 cm in noncontrast abdominopelvic CT (SSDE 30.4 ± 21.8%, CTDIvol 30.8 ± 21.4%). Solely the group of patients with a Dw of 37-41 cm undergoing noncontrast abdominopelvic CT exceeded the ACR DRL (SSDE 100.3 ± 59.0%, CTDIvol 107.1 ± 63.5%).
CONCLUSIONS: On average, mean SSDE and CTDIvol of our institutional chest and abdominopelvic CT protocols were lower than the updated 2017 ACR DRLs. Size-specific subgroup analysis revealed a wide variability of SSDE and CTDIvol across CT protocols and patient size groups with a transgression of DRLs in noncontrast abdominopelvic CT of large patients (Dw 37-41 cm).
引用
- Klosterkemper Y, Appel E, Thomas C, et al. Tailoring CT Dose to Patient Size: Implementation of the Updated 2017 ACR Size-specific Diagnostic Reference Levels. Acad Radiol. 2018. PMID: 29580788. doi:10.1016/j.acra.2018.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。